Enlargement of the heart muscle
POPULARITY
37 episodes with Hypertrophic cardiomyopathy
22 episodes with Hypertrophic cardiomyopathy
9 episodes with Hypertrophic cardiomyopathy
12 episodes with Hypertrophic cardiomyopathy
12 episodes with Hypertrophic cardiomyopathy
11 episodes with Hypertrophic cardiomyopathy
14 episodes with Hypertrophic cardiomyopathy
10 episodes with Hypertrophic cardiomyopathy
10 episodes with Hypertrophic cardiomyopathy
12 episodes with Hypertrophic cardiomyopathy
7 episodes with Hypertrophic cardiomyopathy
12 episodes with Hypertrophic cardiomyopathy
7 episodes with Hypertrophic cardiomyopathy
5 episodes with Hypertrophic cardiomyopathy
4 episodes with Hypertrophic cardiomyopathy
5 episodes with Hypertrophic cardiomyopathy
5 episodes with Hypertrophic cardiomyopathy
4 episodes with Hypertrophic cardiomyopathy
3 episodes with Hypertrophic cardiomyopathy
2 episodes with Hypertrophic cardiomyopathy
4 episodes with Hypertrophic cardiomyopathy
3 episodes with Hypertrophic cardiomyopathy
2 episodes with Hypertrophic cardiomyopathy
7 episodes with Hypertrophic cardiomyopathy
3 episodes with Hypertrophic cardiomyopathy
2 episodes with Hypertrophic cardiomyopathy
7 episodes with Hypertrophic cardiomyopathy
Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
Hypertrophic cardiomyopathy, a genetic heart disease that can cause sudden cardiac death in young athletes and otherwise healthy adults, is difficult for doctors to predict and monitor.
A silent killer hiding in plain sight — and you may not know you're at risk. I talk with a CEO living with this genetic heart condition and what it means for you. Dr. John Phillips and I talk to one of the most respected minds in tech, Phil McKinney, former CTO of Hewlett Packard and now CEO of CableLabs, to talk about something far more personal than innovation: A genetic heart condition he didn't know he had. It's called apical hypertrophic cardiomyopathy, a form of hypertrophic cardiomyopathy where the heart muscle thickens, particularly at the tip of the heart. That thickening can interfere with blood flow and increase the risk of dangerous heart rhythms. And here's what you need to know: Hypertrophic cardiomyopathy affects about 1 in 500 people...many of whom don't even know they have it. For some, the first sign is a life-threatening event. Phil was fortunate. His condition was caught early. Not everyone gets that chance. We break down what this condition actually is, why it's often missed, and how something as simple as knowing your family history could change your outcome. If there's heart disease in your family, or unexplained symptoms like shortness of breath, chest discomfort, dizziness, or fainting, those are not things to brush off. This is about awareness. It's about asking better questions. And it's about catching something early enough to do something about it.
Drs. Maron and Rowin review how treatment for symptomatic obstructive hypertrophic cardiomyopathy has evolved from mainly using beta blockers and invasive procedures to now including newer cardiac myosin inhibitor drugs. These newer medications more reliably reduce obstruction and improve patient symptoms and exercise capacity, but require careful safety monitoring with regular heart function checks.
To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro - MRI Question - Implant Surgery Question - Breast Cancer Question 00:38:19 - Granulomatosis with Polyangiitis (GPA) 00:58:43 - Hypertrophic Cardiomyopathy 01:08:37 - One Kidney - Low Energy - Brain Fog - Hair Loss 01:29:38 - Sleepless - Ringing in the ears - Depression - Anxiety - Obsessive Thoughts - Head Pain 01:35:58 - Neuroendocrine Tumors (NETs) Update with Eye Pictures 01:42:17 - Cervical Cancer Update with Eye Pictures 00:38:19 - Granulomatosis with Polyangiitis (GPA) A scan of her head revealed severe inflammation in her brain. 00:58:43 - Hypertrophic Cardiomyopathy The doctors told me it's genetic, is this true or does lifestyle come into it? 01:08:37 - One Kidney - Low Energy - Brain Fog - Hair Loss I'm unsure if the adrenal gland was removed too. 01:29:38 - Sleepless - Ringing in the ears - Depression - Anxiety - Obsessive Thoughts - Head Pain I have ringing in the ears, depression, anxiety obsessive thoughts and face/head pain, for years. 01:35:58 - Neuroendocrine Tumors (NETs) Update with Eye Pictures Pain from my skeleton that I've had for 4 years is gone 01:42:17 - Cervical Cancer Update with Eye Pictures Was told surgery was not an option.
Commentary by Dr. Shujuan Yang.
Commentary by Dr. Jian'an Wang.
Drs. Maron and Rowin provide an overview of hypertrophic cardiomyopathy, explaining how it is diagnosed by heart imaging and classified into obstructive and non-obstructive forms. They highlight that obstruction is a major cause of symptoms and stress the importance of carefully assessing patients' day-to-day limitations to guide treatment decisions.
This episode covers: Cardiology this Week: A concise summary of recent studies The future of guidelines in an era of big data and AI Exercise in hypertrophic cardiomyopathy Snapshots Host: Sabiha Gati Guests: Kostas Koskinas, Thomas F. Luescher, Michael Papadakis, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2556 Want to watch the extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight a mini-focus issue on hypertrophic cardiomyopathy (HCM), a field undergoing rapid transformation. The discussion centers on the MAPLE-HCM trial comparing aficamten and metoprolol in symptomatic obstructive HCM, highlighting multidomain response analysis and what it means to measure meaningful improvement. Beyond gradients and biomarkers, the conversation explores a critical question: when physiologic surrogates improve, how should we interpret patient-centered outcomes? Framed by the Editor's Page, "What Does Improvement Mean?", this episode examines the evolving role of myosin inhibitors, disease modification, and the tension between surrogate markers and real-world clinical benefit. Additional highlights include disaggregation of Asian ethnicities in heart failure quality-of-care research and emerging evidence on AI-driven ECG models to predict incident heart failure—underscoring JACC's commitment to precision, equity, and innovation. This issue reflects a broader shift across cardiology: transforming once-static diseases into treatable chronic conditions guided by rigorous evidence.
Commentary by Dr. Thomas Zegkos.
"There is a small chance of sudden death."That's a hell of a thing to hear from your cardiologist when you're a guy who runs ten miles a day and feels healthy as fuck. One minute I'm "knocking the cover off the ball" on my stress tests, and the next, I'm being told I have Hypertrophic Cardiomyopathy—a condition where my heart is literally too strong for its own good. It's a diagnosis that could have sent me into a spiral of anxiety, especially after a recent trip to the ER during a family vacation, but it actually led me to the most important mental shift I've ever made.In this episode, I'm sharing the raw details of my heart journey and the specific reframe that changed everything: the moment I stopped asking "Why is this happening to me?" and started asking "Why is this happening for me?" I dive into how this diagnosis actually protected my sons, empowered my team to crush it while I was out of pocket, and forced me to trade frantic intensity for sustainable productivity. I'm also walking you through a powerful exercise to help you take your own current "low point"—whether it's in your health, your business, or your relationships—and rewrite the story in real-time. You don't have to wait ten years to be grateful for a challenge; you can choose to see the benefit of the obstacle today.//Welcome to The Ray J. Green Show, your destination for tips on sales, strategy, and self-mastery from an operator, not a guru.About Ray:→ Former Managing Director of National Small & Midsize Business at the U.S. Chamber of Commerce, where he doubled revenue per sale in fundraising, led the first increase in SMB membership, co-built a national Mid-Market sales channel, and more.→ Former CEO operator for several investor groups where he led turnarounds of recently acquired small businesses.→ Current founder of MSP Sales Partners, where we currently help IT companies scale sales: www.MSPSalesPartners.com→ Current Sales & Sales Management Expert in Residence at the world's largest IT business mastermind.→ Current Managing Partner of Repeatable Revenue Ventures, where we scale B2B companies we have equity in: www.RayJGreen.com//Follow Ray on:YouTube | LinkedIn | Facebook | Twitter | Instagram
In this episode, host Alyssa Watson, DVM, welcomes Andrea C. Eriksson De Rezende, DVM, DACVIM (Cardiology), to discuss her recent Clinician's Brief article, “Hypertrophic Cardiomyopathy in a Cat.” Dr. Eriksson De Rezende covers a variety of presentations, the full list of diagnostics including NT-proBNP, the virtues of sedation, and therapies ranging from the mainstays to that new sirolimus drug. Following this case-based exercise, they go well beyond the basics when it comes to HCM and thromboembolic disease in cats.Resource:https://www.cliniciansbrief.com/article/hypertrophic-cardiomyopathy-catContact:podcast@instinct.vetWhere To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
Patients with cardiomyopathy may benefit from virtual patient support groups. Guest Andrea Linder, RN, MSN, CCRC, FPCNA, describes a successful model, with sessions that include both information and opportunities to share their questions and experiences. Andrea also discusses recent clinical trials and the impact of mavacamten on disease management.Related PCNA Resources:Patient Education Tool on Hypertrophic Cardiomyopathy: https://pcna.net/resource/hypertrophic-cardiomyopathy-what-you-need-to-know-fact-sheet/HCP tool on Hypertrophic Cardiomyopathy: https://pcna.net/resource/hypertrophic-cardiomyopathy-what-healthcare-providers-need-to-know/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
Josue recommends a prolonged warm-up for a patient with hypertrophic cardiomyopathy before initiating aerobic exercise. Which of the following is the MOST likely rationale for this recommendation?A) To increase left ventricular filling timeB) To prevent sudden increases in heart rateC) To increase myocardial oxygen consumptionD) To enhance stroke volume during exerciseDOWNLOAD THIS EPISODE'S CHEATSHEET:www.nptecheatsheet.com/hyper-heart
A look at hypertrophic cardiomyopathy and hypertrophic obstructive cardiomyopathy, including signs and symptoms, pathophysiology of hypertrophic cardiomyopathy and its diagnosis (and murmur!). Also features hypertrophic cardiomyopathy treatment options. PDFs available here: https://rhesusmedicine.com/pages/cardiologyFor more medicine videos consider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Buy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Hypertrophic Cardiomyopathy? 0:14 Hypertrophic Cardiomyopathy Epidemiology0:49 Hypertrophic Cardiomyopathy Pathophysiology / Hypertrophic Obstructive Cardiomyopathy Pathophysiology2:30 Systolic Anterior Motion / Systolic Anterior Movement4:22 Hypertrophic Cardiomyopathy Signs and Symptoms6:07 Hypertrophic Cardiomyopathy Diagnosis7:19 Hypertrophic Cardiomyopathy TreatmentLINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/References:Marian, A.J. & Braunwald, E., 2017. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research, 121(7), pp.749–770. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654557/. PMCLife in the Fast Lane (LITFL), 2025. Hypertrophic Cardiomyopathy (HCM) • ECG Library Diagnosis. [online] Available at: https://litfl.com/hypertrophic-cardiomyopathy-hcm-ecg-library/.BMJ Best Practice, 2025. Hypertrophic cardiomyopathy – Symptoms, diagnosis and treatment. [online] Available at: https://bestpractice.bmj.com/topics/en-gb/409. BMJ Best PracticeDisclaimer: Please remember this video and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RJP865. CME/MOC/AAPA/IPCE credit will be available until October 27, 2026 .Fine-Tuning Hypertrophic Cardiomyopathy Care in the CMI Era: Redefining Management for the Modern Heart Failure Specialist In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RJP865. CME/MOC/AAPA/IPCE credit will be available until October 27, 2026 .Fine-Tuning Hypertrophic Cardiomyopathy Care in the CMI Era: Redefining Management for the Modern Heart Failure Specialist In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RJP865. CME/MOC/AAPA/IPCE credit will be available until October 27, 2026 .Fine-Tuning Hypertrophic Cardiomyopathy Care in the CMI Era: Redefining Management for the Modern Heart Failure Specialist In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RJP865. CME/MOC/AAPA/IPCE credit will be available until October 27, 2026 .Fine-Tuning Hypertrophic Cardiomyopathy Care in the CMI Era: Redefining Management for the Modern Heart Failure Specialist In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
When a cat is diagnosed with hypertrophic cardiomyopathy (HCM), the path forward often feels uncertain, but this innovative development in the treatment of feline HCM is changing the game and carving out clearer treatment paths. In this episode of the Partner Podcast, Dr. Ashlie Saffire explores how a new targeted treatment, Felycin-CA1, may transform not only how veterinarians manage this common feline heart disease but also how we think about screening for subclinical HCM in practice.Sponsored by PRN PharmacalResource:Felycin.comContact us:Podcast@instinct.vetWhere to find us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/X: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostTaylor Argo- Producer, Sound Editing, & Project Manager, Brief Studio
In this podcast accompanying the October issue of DTB (https://dtb.bmj.com/content/63/10) David Phizackerley (DTB Editor) is joined by Julian Treadwell (DTB Associate Editor). David and Julian discuss the editorial that highlights a few of the challenges associated with the introduction of an orphan medicine into clinical practice (https://dtb.bmj.com/content/63/10/146). They talk about a DTB Select article that summarises a randomised clinical trial that assessed the effect of allopurinol on cardiovascular outcomes in people with ischaemic heart disease who did not have gout (https://dtb.bmj.com/content/63/10/147). They finish by discussing the main article that provides an overview of the evidence for mavacamten (▼Camzyos) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults (https://dtb.bmj.com/content/63/10/150). Links GP Evidence: https://gpevidence.org/ Preventing Overdiagnosis 2025 International Conference: https://www.cebm.ox.ac.uk/preventing-overdiagnosis Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.
More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I New European Valvular Heart Disease Guidelines 2025 ESC/EACTS Guidelines for the management of valvular heart disease https://doi.org/10.1093/eurheartj/ehaf194 Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/ Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528 Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336 II New Drug for Resistant HTN Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7 Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109 Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440 III HCM News at ESC New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654 SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424 ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927 IV Vericiguat at ESC New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9 VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4 VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928 An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4 V More on Digoxin RATE AF substudy https://doi.org/10.1002/ejhf.70022 Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407 Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in Children and Adolescents With Hypertrophic Cardiomyopathy.
Dr. Francis Marchlinski, Deputy Editor of JACC: Clinical Electrophysiology, discusses electrical storm in patients with hypertrophic cardiomyopathy.
Commentary by Dr. Jian'an Wang.
Commentary by Dr. Jian'an Wang.
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Myocardial Work in Children With Hypertrophic Cardiomyopathy: Longitudinal Evaluation and Prognostic Implications.
Often, the first symptom of hypertrophic cardiomyopathy is sudden death. But sometimes, we get a warning— and that's where clinical judgment at the bedside saves lives.Today, Sarah goes over the case of her patient Ben, a 20-year-old experiencing syncope and chest pain. As his condition quickly deteriorated, the team had to carefully manage the patient before reaching a diagnosis of hypertrophic cardiomyopathy. Hear what pointed them to this diagnosis, why some standard interventions can be dangerous in HCM cases, and the critical decisions made during his treatment.Listen now for a deep dive into the pathophysiology and treatment of hypertrophic cardiomyopathy!Topics discussed in this episode:Case presentation of a young patient with chest painHow we got to the patient's diagnosis Pathophysiology of hypertrophic cardiomyopathyWhy the patient deteriorated and our treatment approachEmergency management of HCMOther types of cardiomyopathyKey takeaways for bedside nursesListen to episode 98, “Broken Heart Syndrome” aka Takotsubo Cardiomyopathy, here: https://healthpodcastnetwork.com/episodes/rapid-response-rn/98-broken-heart-syndrome-aka-takotsubo-cardiomyopathy/Mentioned in this episode:Listen to the In The Heart of Care Podcasthttps://link.cohostpodcasting.com/6598429e-e927-45b0-9b57-7dd34a09d803?d=seASyqjs7
Steve Dale has his pulse on the veterinary and training world at all times - thats why we call him the Wizard! Join the Amys and certified Animal Behavior Consultant, pet expert, public speaker, and host of Steve Dale's Pet World, the fabulous Steve Dale, as they discuss heart disease in cats and emerging new treatments. They also delve into behavior and training -
Join host Elizabeth S DeWitt, MD, CEPS-P, and episode guests Cheyenne Beach, MD, FHRS, CEPS-P, and Robert Przybylski, MD as they discuss Sudden cardiac death is the leading cause of mortality in children with hypertrophic cardiomyopathy (HCM). Two risk scores—HCM Risk-Kids and PRIMaCY—have been developed to estimate 5-year risk, but their performance in an independent cohort showed limitations. Both tools tended to overestimate risk and showed imperfect ability to distinguish between low- and high-risk patients. However, their predictive accuracy significantly improved when risk assessments were repeated over time during follow-up. https://www.hrsonline.org/education/TheLead https://www.ahajournals.org/doi/abs/10.1161/CIRCEP.124.012932 Host Disclosure(s): E. DeWitt: Nothing to disclose. Contributor Disclosure(s): C. Beach: Nothing to disclose. R. Przybylski: Nothing to disclose.
Better Edge : A Northwestern Medicine podcast for physicians
In this episode of Better Edge, Baljash S. Cheema, MD, assistant professor of Cardiology at Northwestern Medicine, and Zach Miller, PhD, manager of Machine Learning and Artificial Intelligence at Northwestern Medicine, discuss the innovative use of machine learning to identify patients with hypertrophic cardiomyopathy and heart failure. Emphasizing the critical collaboration between clinical experts and data scientists, Dr. Cheema and Dr. Miller explain the process of designing and optimizing AI models to better meet clinician needs and improve patient outcomes.
Hosts Mitsuaki Sawano, MD, Shun Kohsaka, MD, and Nobuhiro Ikemura, MD, welcome Masashi Amano, MD, from the National Cerebral and Cardiovascular Center in Japan, to discuss his recent article titled "Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy," published in JACC: Heart Failure.Drawing from the REVEAL-HCM registry of 3,611 patients across 21 Japanese centers, the study evaluated how well U.S. and European guidelines for ICD implantation apply to Japanese patients with HCM. The findings revealed poor outcomes in end-stage HCM (EF
In this second entry in the JACC-Baran Japanese language series, JACC Executive Associate Editor Mitsuaki Sawano, MD, Shun Kohsaka, MD, FACC, and Yuichi Shimada, MD, MPH, speak on topics ranging from all things Super Bowl to Dr. Shimada's recently published JACC paper, Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.
Host: Darryl S. Chutka, M.D. Guest: Jeffrey B. Geske, M.D. Hypertrophic cardiomyopathy affects 1 in 500 adults or about 600,000 individuals in the U.S. and represents the most common inherited cardiomyopathy. It often goes undetected, and it's estimated that about 85% of those with the condition remain undiagnosed. HCM can produce a variety of symptoms, the most serious being sudden death. The topic for this podcast is Hypertrophic Cardiomyopathy. What are the clues that might make us suspect a patient has HCM and how should we confirm the diagnosis? Are we able to prevent sudden death in patients with the condition and finally, what is the most effective treatment? I'll asking these questions of my guest, Jeffrey B. Geske, M.D., from the Department of Cardiovascular Diseases at Mayo Clinic. For more information on heart health, check out Mayo Clinic Talks: Heart Health | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development
In this episode, we review the high-yield topic Hypertrophic Cardiomyopathy from the Cardiovascular section at Medbullets.com Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
CardioNerds (Dr. Dan Ambinder and guest host, Dr. Pooja Prasad) join Dr. Donny Mattia from Phoenix Children's pediatric cardiology fellowship, Dr. Sri Nayak from the Mayo Clinic – Arizona adult cardiology fellowship, and Dr. Harrison VanDolah from the University of Arizona College of Medicine - Phoenix Med/Peds program for a sunrise hike of Piestewa Peak, followed by some coffee at Berdena's in Old Town Scottsdale (before the bachelorette parties arrive), then finally a stroll through the Phoenix Desert Botanical Gardens to discuss a thought-provoking case series full of clinical cardiology pearls. Expert commentary is provided by Dr. Tabitha Moe. Episode audio was edited by Dan Ambinder. They discuss the following case: Cardiology is consulted by the OB team for a 27-year-old female G1, now P1, who has just delivered a healthy baby boy at 34 weeks gestation after going into premature labor. She is experiencing shortness of breath and is found to have a significant past cardiac history, including atrial fibrillation and preexcitation, now with a pacemaker and intracardiac defibrillator. We review the differential diagnosis for peripartum cardiomyopathy (PPCM) and then combine findings from her infant son, who is seen by our pediatric cardiology colleagues and is found to have severe hypertrophic cardiomyopathy (HCM). Genetic testing for both ultimately reveals a LAMP2 mutation consistent with Danon Disease. The case discussion focuses on the differential diagnosis for PPCM, HCM, pearls on Danon Disease and other HCM “phenocopies,” and the importance of good history. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media Pearls Peripartum cardiomyopathy is a diagnosis of exclusion – we must exclude other possible etiologies of heart failure! Be on the lookout for features of non-sarcomeric HCM – as Dr. Michelle Kittleson said in Episode 166, “LVH plus” states. HCM with preexcitation, heart block, strong family history, or extracardiac symptoms such as peripheral neuropathy, myopathy, or cognitive impairment should be evaluated for infiltrative/inherited cardiomyopathies! As an X-linked dominant disorder, Danon disease will present differently in males vs females, with males having much more severe and earlier onset disease with extracardiac features. Making the diagnosis for genetic disorders such as Danon disease is important for getting the rest of family members tested as well as the opportunity for specialized treatments such as gene therapy Up to 5% of Danon disease cases may be due to copy number variants, which may be missed in genetic testing that does not do targeted deletion/duplication analysis!). Notes What is the differential diagnosis for peripartum cardiomyopathy? Peripartum cardiomyopathy is a diagnosis of exclusion – we must exclude other possible etiologies of heart failure! First, ensure that you are not missing an acute life-threatening etiology of acute decompensated heart failure – pulmonary embolism, amniotic fluid embolism, ACS, and SCAD should all be ruled out. Second, a careful history can identify underlying heart disease or risk factors for the development of heart failure, such as substance use, high-risk behaviors that put one at risk for HIV infection, and family history that suggests an inheritable cardiomyopathy. Lastly, a careful review of echocardiographic imaging may also identify underlying etiologies that warrant a change in management. Diagnosis of peripartum cardiomyopathy is important to consider as within 7 days of onset, patients may be eligible for treatment with bromocriptine – consider referring ...
© 2020-2026 Ivy Podcast Discovery LLC
